Evicenter
P&T meetings

Deramiocel (CAP-1002)

Duchenne muscular dystrophy

Launch
Not announced
Last updated
92 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Gene replacement therapy

2 evidence topics · 1 source

Delandistrogene moxeparvovec: revised eligible population

“ambulatory patients with DMD who are 4 years of age and older with a confirmed mutation in the DMD gene” (opens the source at this quote in a new tab)

Other treatment options: delandistrogene moxeparvovec

“serious liver injury and acute liver failure, including fatal outcomes” (opens the source at this quote in a new tab)

“Removal of the indication for non-ambulatory patients with DMD” (opens the source at this quote in a new tab)